(1,3)-Béta-D-Glucan Levels at Diagnosis of Juvenile Idiopathic Arthritis and Its Correlation With Activity's Disease : a Cohort Sudy

(1,3)-Béta-D-Glucan Levels at Diagnosis of Juvenile Idiopathic Arthritis and Its Correlation With Activity's Disease : a Cohort Sudy

Sponsors

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Source Centre Hospitalier Universitaire, Amiens
Brief Summary

Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease of childhood. Most children still experience prolonged periods of active disease, however, there is still lack of effective and specific markers for early diagnosis of relapse. The pathogenesis of JIA is thought to be the result of a combination of host genetic and environmental triggers and The microbiota is a potential contributing factor to the development of the disease. (1-3)-ß-D-Glucan (BDG), a component of most fungal cell walls, possess immunomodulatory activities. Latest studies demonstrate that it acts as a trigger for autoimmune arthritis in adult. However the relation with JIA is not clearly defined. The objective of this study was to evaluate the (1,3)-Béta-D-Glucans level in patients with JIA and whether higher serum BDG levels are correlated with JIA activity of disease, comparatively with usual markers.

Overall Status Recruiting
Start Date June 11, 2019
Completion Date June 2020
Primary Completion Date June 2020
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Measure of (1,3)-Beta-D-Glucans level in patients with Juvenile Idiopathic Arthritis one year
Secondary Outcome
Measure Time Frame
Correlation of (1,3)-Beta-D-Glucans level in patients with Juvenile Idiopathic Arthritis score (JADAS) one year
Enrollment 40
Condition
Intervention

Intervention Type: Diagnostic Test

Intervention Name: The Juvenile Disease Activity Score (JADAS)

Description: The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.

Intervention Type: Biological

Intervention Name: (1-3)-ß-D-Glucan (BDG) assay (Fungitell)

Description: Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers

Eligibility

Criteria:

Inclusion Criteria:

- All patients under the age of 18 years with JIA's disease

- followed at the CHU Amiens (French University hospital)

- signed parent consent form

Exclusion Criteria:

- lack of consent from parents or patient

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No

Overall Official
Overall Contact

Last Name: Djamal-Dine Djeddi, MD

Phone: (33)322087632

Email: [email protected]

Location
Facility: Status: Contact: Contact Backup: CHU Amiens Djamal-Dine Djeddi, MD (33)322087632 [email protected]
Location Countries

France

Verification Date

June 2019

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Acronym BDG -JIA
Patient Data No
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Diagnostic

Masking: None (Open Label)

Source: ClinicalTrials.gov